No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.

2.50
Hdl Handle:
http://hdl.handle.net/10541/109324
Title:
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.
Authors:
Hawkins, Neil; Scott, David A; Woods, Beth S; Thatcher, Nick
Abstract:
OBJECTIVE: To demonstrate the importance of considering all relevant indirect data in a network meta-analysis of treatments for non-small-cell lung cancer (NSCLC). METHODS: A recent National Institute for Health and Clinical Excellence appraisal focussed on the indirect comparison of docetaxel with erlotinib in second-line treatment of NSCLC based on trials including a common comparator. We compared the results of this analysis to a network meta-analysis including other trials that formed a network of evidence. We also examined the importance of allowing for the correlations between the estimated treatment effects that can arise when analysing such networks. RESULTS: The analysis of the restricted network including only trials of docetaxel and erlotinib linked via the common placebo comparator produced an estimated mean hazard ratio (HR) for erlotinib compared with docetaxel of 1.55 (95% confidence interval [CI] 0.72-2.97). In contrast, the network meta-analysis produced an estimated HR for erlotinib compared with docetaxel of 0.83 (95% CI 0.65-1.06). Analyzing the wider network improved the precision of estimated treatment effects, altered their rankings and also allowed further treatments to be compared. Some of the estimated treatment effects from the wider network were highly correlated. CONCLUSIONS: This empirical example shows the importance of considering all potentially relevant data when comparing treatments. Care should therefore be taken to consider all relevant information, including correlations induced by the network of trial data, when comparing treatments.
Affiliation:
Oxford Outcomes Ltd., Oxford, UK. neil.hawkins@oxfordoutcomes.com
Citation:
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. 2009, 12 (6):996-1003 Value Health
Journal:
Value in Health
Issue Date:
Sep-2009
URI:
http://hdl.handle.net/10541/109324
DOI:
10.1111/j.1524-4733.2009.00541.x
PubMed ID:
19402854
Type:
Article
Language:
en
ISSN:
1524-4733
Appears in Collections:
All Christie Publications ; Medical Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorHawkins, Neilen
dc.contributor.authorScott, David Aen
dc.contributor.authorWoods, Beth Sen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-08-09T14:49:44Z-
dc.date.available2010-08-09T14:49:44Z-
dc.date.issued2009-09-
dc.identifier.citationNo study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. 2009, 12 (6):996-1003 Value Healthen
dc.identifier.issn1524-4733-
dc.identifier.pmid19402854-
dc.identifier.doi10.1111/j.1524-4733.2009.00541.x-
dc.identifier.urihttp://hdl.handle.net/10541/109324-
dc.description.abstractOBJECTIVE: To demonstrate the importance of considering all relevant indirect data in a network meta-analysis of treatments for non-small-cell lung cancer (NSCLC). METHODS: A recent National Institute for Health and Clinical Excellence appraisal focussed on the indirect comparison of docetaxel with erlotinib in second-line treatment of NSCLC based on trials including a common comparator. We compared the results of this analysis to a network meta-analysis including other trials that formed a network of evidence. We also examined the importance of allowing for the correlations between the estimated treatment effects that can arise when analysing such networks. RESULTS: The analysis of the restricted network including only trials of docetaxel and erlotinib linked via the common placebo comparator produced an estimated mean hazard ratio (HR) for erlotinib compared with docetaxel of 1.55 (95% confidence interval [CI] 0.72-2.97). In contrast, the network meta-analysis produced an estimated HR for erlotinib compared with docetaxel of 0.83 (95% CI 0.65-1.06). Analyzing the wider network improved the precision of estimated treatment effects, altered their rankings and also allowed further treatments to be compared. Some of the estimated treatment effects from the wider network were highly correlated. CONCLUSIONS: This empirical example shows the importance of considering all potentially relevant data when comparing treatments. Care should therefore be taken to consider all relevant information, including correlations induced by the network of trial data, when comparing treatments.en
dc.language.isoenen
dc.subjectAnticancerous Agentsen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshBias (Epidemiology)-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshData Interpretation, Statistical-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshProportional Hazards Models-
dc.subject.meshProtein Kinase Inhibitors-
dc.subject.meshQuinazolines-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshResearch Design-
dc.subject.meshTaxoids-
dc.subject.meshYoung Adult-
dc.titleNo study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.en
dc.typeArticleen
dc.contributor.departmentOxford Outcomes Ltd., Oxford, UK. neil.hawkins@oxfordoutcomes.comen
dc.identifier.journalValue in Healthen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.